Cubist Pharmaceuticals Names Thomas Slater as Vice President, Commercial DevelopmentCubist Pharmaceuticals, Inc.
...CUBIST PHARMACEUTICALS NAMES THOMAS SLATER AS VICE PRESIDENT, COMMERCIAL DEVELOPMENT
Cambridge, MA, May 25, 1999 - Cubist Pharmaceuticals, Inc.
(Nasdaq: CBST) today announced the appointment of Thomas Slater
as Vice President, Commercial Development.Mr. Slater
will be responsible for the marketing, commercialization and partnering strategies of daptomycin and follow-on drug candidates.In this newly created position, Mr. Slater will report to Scott Rocklage, Ph.D. President and CEO of Cubist.
brings to Cubist
over twenty years of pharmaceutical and biotech sales, marketing and commercial development experience from Genzyme and Hoffman LaRoche.He most recently served as Vice President, Biomaterials Business at Genzyme and was responsible for all commercialization and strategic activities of the Biomaterials Business.Mr. Slater's
appointment is another key addition to help Cubist advance daptomycin to the market as quickly as possible.
I am very pleased we have hired such an enthusiastic and talented individual as Tom
to manage and refine our plans."
Daptomycin is a novel antibiotic currently in Phase III clinical trials to evaluate safety and efficacy in treating complicated skin and soft tissue infections and in a Phase II trial to treat bloodstream infections not associated with endocarditis.Interim results from the Phase II open label bacteremia trial are scheduled to be reviewed mid-year.Cubist Pharmaceuticals, Inc.
is a biopharmaceutical company focused on the research, development and commercialization of novel antimicrobial drugs to combat serious and life threatening bacteria and fungi infections.Cubist
is engaged in strategic partnerships with Novartis Pharma AG, Merck & Co., Inc.
and Bristol-Myers Squibb
for the discovery and development of novel antiinfective products, and has formed biotechnology alliances with ArQule, Inc., Helios, Inc.
, and Neurogen Corporation